NCT06952803 2026-04-21
EvoPAR-PR02
AstraZeneca
Phase 3 Recruiting
Clinical Trials
13 trialsNCT06925737 2026-04-20
MK-2400-001
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06764485 2026-01-28
rechARge
Celgene
Phase 3 Recruiting
NCT07365995 2026-01-26
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
BioNTech SE
Phase 3 Not yet recruiting
NCT05288166 2025-06-27
CYCLONE 3
Eli Lilly and Company
Phase 3 Active not recruiting
NCT03072238 2025-06-06
IPATential150
Hoffmann-La Roche
Phase 3 Completed
NCT03834519 2025-05-18
KEYLYNK-010
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02288247 2025-04-08
PRESIDE
Astellas Pharma Inc
Phase 3 Completed
NCT02043678 2025-02-19
ERA 223
Bayer
Phase 3 Completed
NCT06768255 2025-01-10
mCRPC
Fudan University
Phase 3 Not yet recruiting
NCT01308580 2017-04-17
PROSELICA
Sanofi
Phase 3 Completed
NCT00519285 2016-07-22
VENICE
Sanofi
Phase 3 Completed
NCT00638690 2014-04-30
Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Cougar Biotechnology, Inc.
Phase 3 Completed